NMS-341 / Nerviano Medical Sciences - LARVOL DELTA

Nerviano Medical Sciences announces strategic portfolio shaping. (NMS Group) - "Nerviano Medical Sciences S.r.l...announces the strategic discontinuation of three development programs to further prioritize and reinforce efforts on core programs. NMS-088...The decision is the result of internal analysis of the benefit profile of the drug in the third line (3L) setting in patients who are refractory or relapsed after standard of care including prior FLT3 inhibitors and considering the further development in rapidly changing AML treatments. NMS will report the data in in the first half of 2025...NMS-173, a potent covalent orally available, second-generation dual IDH1/ IDH2 inhibitor...NMS-341, a late preclinical-stage next-generation inhibitor of CDC7..."

Clinical data • Discontinued • Acute Myelogenous Leukemia • Biliary Tract Cancer • Cholangiocarcinoma • Hematological Malignancies • Leukemia • Oncology • Solid Tumor